Categories: ActiveDeliveryITMedtechResearchTime
Palto Therapeutics AG is a new Swiss company founded by research scientists with an extensive background in pharmaceutical research. We are 100% privately funded by the founders and not yet commercially active. Palto Therapeutics has developed an innovative concept that integrates all necessary functions to overcome small RNA delivery and targeting problems. Palto Therapeutics has designed a nano-structure called SmartCoat that physically protects the siRNA against degradation and tissue adsorption, has excellent antibody-like pharmacokinetic properties and allows targeted delivery to cell types and organs of choice. The nanostructure is small (6 nM) and forms a defined 1:1 complex. At the same time, it is non-immunogenic, degradable, and binds to any siRNA without modification.
Investors 1
Mentions in press and media 3
Reviews 0
